Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
methotrexate + doxorubicin + cisplatin
- Development stage
- Phase 3
- Lead developer
- Farmitalia
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
The MAP regimen is a standard chemotherapy combination consisting of methotrexate, doxorubicin (adriamycin), and cisplatin. It is primarily used for the treatment of osteosarcoma, a type of bone cancer. This combination has been established as the standard of care for conventional osteosarcoma treatment. The regimen typically involves systemic multidrug chemotherapy that can be administered both preoperatively (neoadjuvant) and postoperatively (adjuvant). Postoperative adjuvant chemotherapy with MAP has been shown to improve disease-free and overall survival in patients with osteosarcoma.
- Other names
- MAP regimen
02
Targets
DNATOP2A (DNA topoisomerase II)DHFR (Dihydrofolate reductase)
Beyond the preview
Go deeper on methotrexate + doxorubicin + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on methotrexate + doxorubicin + cisplatin.